Frequency of human papilloma virus in squamous cell atypia of undetermined significance: Case series

Frecuencia de virus del papiloma humano en atipia de células escamosas de significado infeterminado: Serie de casos

Cervical cancer results from persistent infection with the human papillomavirus (HPV). Global health policies are based on screening programs to reduce the incidence of cancer. Tests have been implemented to detect HPV and thus clarify ambiguous cytomorphological reports such as squamous cell atypia of undetermined significance (ASC-US), to optimize the management of these cytological results. Objectives: to establish the frequency of high risk HPV by means of molecular test in women diagnosed with ASC-US by conventional cytology in the Hospital of San José de Bogotá DC. Methods: series of cases with conventional cytology, colposcopy and HPV test, followed up at six months. Results: of 121 patients, 16% had ASC-US diagnosis and in 15% of these, the high-risk HPV test was positive. Conclusions: the frequency of HPV in cases with ASCUS was 15%, comparable with that reported in the literature, and in the entire sample, HPV was 11.5%. Of the risk factors, no relationship was found with early onset of sexual relations and the number of sexual partners. Abbreviations: HPV, human papillomavirus; ASC-US, atypia of squamous cells of undetermined significance: BR, low risk; AR; high risk.

1. Castellsaguè X, Llongueras S, Bosch FX. Epidemiología de la infección por VPH y del cáncer de cuello de útero. Nuevas opciones preventivas. En: Carreras Collado R, Xercavins Montosa J, Checa Vizcaíno MA. Virus del papiloma humano y cáncer de cuello de útero. Buenos Aires: Editorial Médica Panamericana; 2007.

2. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiolo gy, prevention and the role of human papillomavirus infection. CMAJ.2001;164(7):1017-25.

3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917.

4. WHO, International Angency for Research On Cancer. Globocan 2012. Estimated incidence, mortality and prevalence worldwide in 2012 [monograph on the Internet]. Lyon, France: IARC, World Health Organitation; 2012 [cited 2014 may 20]. Disponible en: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.

5. Borré Arrieta O, Redondo C. Patología premaligna y maligna de cérvix [mono-grafía en Internet]. Cartagena, Colombia: Clínica de Maternidad Rafael Calvo; 2012 [citado 2014 mayo 20]. Disponible en: http://www.maternidadrafaelcalvo.gov.co/protocolos/PROTOCOLO_PATOLOGIA_PREMALIGNA_Y_MALIGNA_DE_CE.pdf.

6. Macgregor JE, Campbell MK, Mann EM, Swanson KY. Screening for cervical intraepithelial neoplasia in north east Scotland shows fall in incidence and mortality from invasive cancer with concomitant rise in preinvasive disease. BMJ. 1994;308(6941):1407-11.

7. McKinley E. Principios generales de citología. En: Atkinson BF, editor. Atlas de diagnóstico citopatológico. Madrid: Elsevier; 2011. p. 1-13.

8. Tamayo R. Prólogo. En: Alonso de Ruiz P, Lazcano Ponce EC, Hernández Ávila M, editores. Cáncer cervicouterino: diagnóstico, prevención y control. Buenos Aires: Editorial Médica Panamericana; 2005.

9. Quinn M, Babb P, Jones J, Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ. 1999;318(7188):904-8.

10. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet. 2004; 364(9430):249-56.

11. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.

12. Sherman ME, Abdul-Karim F. Células escamosas atípicas. En: Solomon D, Nayar R, editores. El Sistema Bethesda para informar la citología cervical : definiciones, criterios y notas aclaratorias. Buenos Aires: Journal; 2005.

13. Doorbar J. The papillomavirus life cycle. J Clin Virol. 2005;32 Suppl 1:S7-15.

14. Stoler MH, Wright TC Jr, Sharma A, Apple R, Gutekunst K, Wright TL, et al. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol. 2011;135(3):468-75.

15. Dahl MB, Ejersbo D, Holund B. [Cause and follow-up of inadequate cervical smears in the county of Funen]. Ugeskr Laeger. 2002;164(37):4280-3.

16. Colgan TJ. Programmatic assessments of the clinical effectiveness of gynecologic liquid-based cytology. Cancer. 2003;99(5):259-62.

17. Castle PE, Sadorra M, Lau T, Aldrich C, Garcia FA, Kornegay J. Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping. J Clin Microbiol. 2009;47(10):3344-7.

18. Castellsague X, Bosch FX, Munoz N, Meijer CJ, Shah KV, de Sanjose S, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med. 2002;346(15):1105-12.

19. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005;337(1):76-84.

20. Sargent A, Bailey A, Almonte M, Turner A, Thomson C, Peto J, et al. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer. 2008;98(10):1704-9.

21. Roset Bahmanyar E, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, et al. Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecol Oncol. 2012;127(3):440-50.

22. ASCUS-LSIL Traige Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003;188(6):1383-92.

23. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results. J Low Genit Tract Dis. 2013;17(5 Suppl 1):S36-42.

24. Einstein MH, Martens MG, Garcia FA, Ferris DG, Mitchell AL, Day SP, et al. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol Oncol. 2010;118(2):116-22.

25. Gage JC, Schiffman M, Solomon D, Wheeler CM, Castle PE. Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions. Cancer Epidemiol Biomarkers Prev. 2010;19(7):1668-74.

26. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93(4):293-9.

27. Pimentel VM, Jiang X, Mandavilli S, Umenyi Nwana C, Schnatz PF. Prevalence of high-risk cervical human papillomavirus and squamous intraepithelial lesion in Nigeria. J Low Genit Tract Dis. 2013;17(2):203-9.

28. Mu-Mu-Shwe, Harano T, Okada S, Aye-Aye-Win, Khin-Saw-Aye, Hlaing-Myat-Thu, et al. Prevalence of high-risk human papillomavirus (HR-HPV) infection among women with normal and abnormal cervical cytology in Myanmar. Acta Med Okayama. 2014;68(2):79-87.